Literature DB >> 1269216

Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.

D Lalka, M B Meyer, B R Duce, A T Elvin.   

Abstract

Tocainide, a primary amine analogue of lidocaine, is effective against some experimental and clinical arrhythmias. Its pharmacokinetic behavior was studied in 6 healthy male subjects. Peak blood levels (CB max) and area under the blood concentration-time curve (AUC) were linearly related to dose with slopes of 0.0067 mcg/ml and 6 min mcg/ml per milligram of dose, respectively. Renal clearance of tocainide averaged 59 ml/min when urinary pH was uncontrolled or acidified, while it was reduced to 13 ml/min during intense sodium bicarbonate loading. Blood levels following intravenous infusion were well described by a 2-compartment open model with a volume of the central compartment of 0.92 L/kg. The t 1/2 beta was 11 hr and total body clearance was 166 ml/min. Loo-Riegelman analysis of the absorption rate did not allow unequivocal assignment of an "order" to the absorption process. Bioavailability approached 100%. Administration of drug 5 min after a test meal suppressed CB max 40% but minimally affected AUC. Approximately 50% of the drug was found to be plasma protein bound at clinically effective concentrations.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1269216     DOI: 10.1002/cpt1976196757

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  High-performance liquid chromatographic analysis of tocainide in human plasma.

Authors:  L Conings; N Verbeke
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

3.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

4.  The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.

Authors:  A H Thomson; G Murdoch; A Pottage; A W Kelman; B Whiting; W S Hillis
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

Review 5.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

6.  Tocainide protein binding in normal volunteers and trauma patients.

Authors:  A T Elvin; J E Axelson; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

7.  Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.

Authors:  D Oltmanns; A Pottage; W Endell
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.

Authors:  R A Allen-Narker; C J Roberts; A J Marshall; S C Jordan; D W Barritt; R M Goodfellow
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 10.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.